ETON News and Press, Eton Pharmaceutcials Inc. From 10/23/25

DEER PARK, Ill., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report third...

2025-10-10 17:18:54 ET Shares of biopharmaceutical concern Monopar Therapeutics Inc. ( MNPR ) have had an absolutely massive surge in the past year after being left for dead with cash of $7.1 million and a market cap under $9 million. Its acquisition of Wilson disease candidate ALXN-184...

2025-09-24 10:30:04 ET Eton Pharmaceuticals, Inc. (NASDAQ: ETON) is the focus of IBN’s latest stock spotlight. The company’s shares have moved 0.28% on the day to $19.89. Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commerci...

2025-08-15 09:42:45 ET Eton Pharmaceuticals, Inc. (NASDAQ: ETON) is the focus of IBN’s latest stock spotlight. The company’s shares have moved -1.44% on the day to $16.46. Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commerc...

2025-08-13 10:20:25 ET Eton Pharmaceuticals, Inc. (NASDAQ: ETON) is the focus of IBN’s latest stock spotlight. The company’s shares have moved -0.66% on the day to $17.2. Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commerci...

2025-08-08 15:28:30 ET More on Eton Pharmaceuticals Eton Pharmaceuticals, Inc. (ETON) Q2 2025 Earnings Call Transcript Eton Pharmaceuticals: Growth At A Reasonable Price, Or Maybe Even Better With Options Eton Pharma Near Term Catalysts Vanish Eton gains as h...

2025-08-08 15:27:44 ET Eton Pharmaceuticals, Inc. (ETON) Q2 2025 Earnings Conference Call August 07, 2025, 04:30 PM ET Company Participants David C. Krempa - Chief Business Officer James R. Gruber - CFO, Treasurer & Secretary Sean E. Brynjelsen - President, C...

2025-08-08 05:02:13 ET Investment Thesis Small biotech companies are usually “very high risk, but even higher reward”. In general, I look for companies that meet criteria such as: One-two approved products, and with positive cash-flow to be able to focus on pipel...

2025-08-07 16:11:23 ET More on Eton Pharmaceuticals Eton Pharma Near Term Catalysts Vanish Eton Pharmaceuticals: Rapid Revenue Growth And Pipeline Catalysts Point To More Upside Eton Pharmaceuticals Set To Dominate Orphan Drug Niche Eton gains as hormonal dis...

Q2 2025 product sales of $18.9 million, representing 108% growth over Q2 2024 and the 18 th straight quarter of sequential product sales growth Q2 2025 basic and fully diluted GAAP EPS of $(0.10), non-GAAP fully diluted EPS of $0.03, and Adjusted EBITDA of $3.1 million Launched KHINDI...